FPS
VIVO

Fieldpoint Private Securities’s Meridian Bioscience Inc VIVO Stock Holding History

Fieldpoint Private Securities’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-90
Closed -$2K – 1765
2022
Q1 		$2K Buy
+90
New +$2.14K ﹤0.01% 1529
2021
Q4 		– Sell
-55
Closed -$1K – 1762
2021
Q3 		$1K Sell
55
-45
-45% -$897 ﹤0.01% 1627
2021
Q2 		$2K Sell
100
-30
-23% -$636 ﹤0.01% 1426
2021
Q1 		$3K Buy
+130
New +$3.09K ﹤0.01% 1347

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $13.1B AUM 19.56% 1-Year Est. Return

Fieldpoint Private Securities's VIVO Position: Q2 2022 in Review

Fieldpoint Private Securities sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 90 shares — an estimated $2K sold.

Fieldpoint Private Securities first reported a position in VIVO in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q1 2021. 215 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

  • Fieldpoint Private Securities reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
  • Fieldpoint Private Securities sold 90 Meridian Bioscience Inc shares in Q2 2022, an estimated $2K.
  • Fieldpoint Private Securities first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 4 quarters.
  • Fieldpoint Private Securities's Meridian Bioscience Inc position peaked at $3K in Q1 2021.
  • 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.